Global Monoclonal Antibodies (mAbs) Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Production Type;

In vitro and In vivo.

By Indications Cancer;

Autoimmune Diseases, Inflammatory Diseases, Infectious Diseases, Microbial Diseases, and Others

By End Use;

Hospitals, Research Institute, and Others.

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn356282903 Published Date: March, 2025 Updated Date: May, 2025

Introduction

Global Monoclonal Antibodies (mAbs) Market (USD Million), 2021 - 2031

In the year 2024, the Global Monoclonal Antibodies (mAbs) Market was valued at USD 196,247.06 million. The size of this market is expected to increase to USD 387,323.92 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 10.2%.

The global monoclonal antibodies (mAbs) market has become a cornerstone of modern medicine, driven by the rising prevalence of chronic diseases, rapid advancements in biotechnology, and growing healthcare investments. These lab-engineered molecules, designed to function as substitute antibodies, play a vital role in enhancing or mimicking the immune system's ability to target and destroy harmful cells. With their ability to precisely target specific antigens, monoclonal antibodies have transformed the treatment landscape for various conditions, including cancer, autoimmune disorders, infectious diseases, and cardiovascular diseases. Their high specificity and effectiveness have made mAbs indispensable in both diagnostics and therapeutics.

The increasing incidence of chronic conditions, such as cancer, rheumatoid arthritis, and multiple sclerosis, is one of the key drivers propelling the growth of the mAbs market. As the global population continues to age, the prevalence of these diseases is projected to rise, creating a greater demand for advanced treatment options. Monoclonal antibodies have already shown considerable clinical success in cancer treatments, boosting their adoption and fostering the development of new mAb-based therapies. The COVID-19 pandemic further underscored the importance of mAbs in managing infectious diseases, with several monoclonal antibodies receiving emergency use authorization for COVID-19 treatment, which in turn has accelerated market growth. As a result, the mAbs market is anticipated to grow at an annual rate of around 12-15% in the coming years.

Technological innovations such as genetic engineering, recombinant DNA technology, and hybridoma methods have been instrumental in advancing the production of monoclonal antibodies. These breakthroughs not only enhance the safety and efficacy of mAbs but also enable the development of humanized and fully human antibodies, which significantly reduce the risk of immunogenicity and adverse reactions. The expanding pipeline of monoclonal antibodies at various stages of clinical trials indicates a promising outlook for the market. Additionally, growing investments in research and development from pharmaceutical companies, alongside supportive regulatory frameworks, are expected to drive global market growth by 10-20% in the near future.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Production Type
    2. Market Snapshot, By Indications Cancer
    3. Market Snapshot, By End Use
    4. Market Snapshot, By Region
  4. Global Monoclonal Antibodies (mAbs) Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Rising Burden of Chronic Illnesses
        2. Breakthroughs in Biotech and Genetics
        3. Expanding Use in Oncology Care
        4. Surging Demand for Monoclonal Antibodies
      2. Restraints
        1. Elevated R&D and Manufacturing Costs
        2. Tight Global Regulatory Frameworks
        3. Access Barriers in Low-Income Regions
        4. Patent Cliffs and Biosimilar Pressure
      3. Opportunities
        1. Innovation in Next-Gen Antibody Design
        2. Growth Opportunities in Emerging Markets
        3. Rise of Precision and Targeted Care
        4. Strategic Alliances and Collaborations
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Monoclonal Antibodies (mAbs) Market, By Production Type, 2021 - 2031 (USD Million)
      1. In vitro
      2. In vivo
    2. Global Monoclonal Antibodies (mAbs) Market, By Indications Cancer, 2021 - 2031 (USD Million)

      1. Cancer

      2. Autoimmune Diseases

      3. Inflammatory Diseases

      4. Infectious Diseases

      5. Microbial Diseases

      6. Others

    3. Global Monoclonal Antibodies (mAbs) Market, By End Use, 2021 - 2031 (USD Million)
      1. Hospitals
      2. Research Institute
      3. Others
    4. Global Monoclonal Antibodies (mAbs) Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Novartis International
      2. Pfizer
      3. GlaxoSmithKline Plc
      4. Amgen Inc
      5. Merck
      6. Daiichi Sankyo
      7. Abbott Laboratories
      8. AstraZeneca plc
      9. Eli Lilly
      10. Johnson & Johnson
  7. Analyst Views
  8. Future Outlook of the Market